Featured Research

from universities, journals, and other organizations

A New Target In The War On Cancer

Date:
February 26, 2007
Source:
American Chemical Society
Summary:
A new family of potential anti-cancer drugs is quietly causing excitement in the pharmaceutical industry as early data from clinical trials shows promising responses in patients, according to an article scheduled for the Feb. 26 issue of Chemical & Engineering News.

A new family of potential anti-cancer drugs is quietly causing excitement in the pharmaceutical industry as early data from clinical trials shows promising responses in patients, according to an article scheduled for the Feb. 26 issue of Chemical & Engineering News (C&EN), the ACS' weekly newsmagazine.

In the article, C&EN associate editor Lisa Jarvis explains that the new compounds may circumvent the long-standing problem of drug resistance, in which anti-cancer drugs gradually loose their effectiveness.

The drugs focus on a new target in the war against cancer — a substance called heat shock protein 90 (Hsp90). Heat shock proteins are most active when the cell is exposed to elevated temperatures, infection, inflammation, toxins and other stresses that can cause a protein to unfold. Like housekeepers, heat shock proteins help those proteins — including mutated, cancer-causing proteins — get back into their proper shape.

When Hsp90's effects are blocked in cancer cells, those cancer-causing proteins cannot survive, potentially stopping the disease in its track. When Hsp90's effects are blocked in cancer cells, damaged proteins accumulate, and the cell dies. Jarvis explains that cancer cells, with their horribly mutated proteins, seem to be especially dependent on Hsp90, and more vulnerable than other body cells when Hsp90's effects are blocked.

The article describes how new discoveries have changed heat shock proteins from laboratory curiosities into some of today's most promising targets for developing new drugs.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "A New Target In The War On Cancer." ScienceDaily. ScienceDaily, 26 February 2007. <www.sciencedaily.com/releases/2007/02/070226095825.htm>.
American Chemical Society. (2007, February 26). A New Target In The War On Cancer. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/02/070226095825.htm
American Chemical Society. "A New Target In The War On Cancer." ScienceDaily. www.sciencedaily.com/releases/2007/02/070226095825.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins